David Jolley

Whole Genome Sequencing Accelerates Across Europe: How Illumina and the NHS Are Shaping the Future of Precision Medicine February 12, 2026 David Jolley 4:39 pm Summary During the 2026 Festival of Genomics & Biodata, Illumina’s UK General Manager Mark Robinson discussed how whole‑genome sequencing (WGS) is redefining what’s possible in precision medicine. WGS provides an

Servier Launches €200M Venture Fund to Close Europe’s Early Stage Biotech Funding Gap February 12, 2026 David Jolley 4:37 pm Summary Servier, the French pharmaceutical company, has launched a €200 million venture fund—one of the largest new pharma‑backed VC vehicles in recent years—to accelerate investment into Europe’s biotech ecosystem. According to Alexis Vandier, head of

Women in Biotech 2026: Inspiring Leaders Advancing Science, Investment and Innovation Across Europe February 12, 2026 David Jolley 4:35 pm Summary Labiotech’s Women in Biotech 2026 feature spotlights a cohort of influential female leaders shaping the future of Europe’s biotech and life sciences ecosystem. These women span roles in research, venture capital, company building, executive

UK Biotech Poised for Renewal in 2026 Despite Funding Declines and Pharma Pullbacks February 12, 2026 David Jolley 4:33 pm Summary A new Labiotech analysis of the BioIndustry Association (BIA) 2025 report shows that UK biotech entered 2026 with renewed investor confidence despite a challenging year marked by a 13.2% drop in investment, major pharma

Super Bowl 60 Becomes the ‘Pharma Bowl’: How Health Brands Took Centre Stage in the Biggest Ad Event of 2026 February 12, 2026 David Jolley 4:31 pm Summary Super Bowl 60 marked a turning point for pharmaceutical advertising, with five major pharma and health brands—Novo Nordisk, Hims & Hers, Ro, Novartis and Boehringer Ingelheim—running national

Eight ADC Innovators Reshaping Targeted Oncology: Emerging Biotechs Driving the Next Wave of Antibody–Drug Conjugates February 12, 2026 David Jolley 4:29 pm Summary Labiotech highlights eight emerging biotech companies advancing the next generation of antibody–drug conjugates (ADCs). While ADCs have matured into a validated therapeutic modality, limitations with toxicity, linker stability, and target selection have

Big Pharma’s 2025 Earnings Reveal Growth Ambitions Amid Pricing Pressure and Patent Headwinds February 12, 2026 David Jolley 3:48 pm Summary Big Pharma’s latest earnings commentary highlights how Johnson & Johnson (J&J), Pfizer and Merck are navigating political pressure, pricing reform, and looming patent losses while still projecting major long‑term revenue growth. J&J emphasised its